Pfizer Inc. (NYSE:PFE) Shares Acquired by Hexagon Capital Partners LLC

Hexagon Capital Partners LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 4.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,730 shares of the biopharmaceutical company’s stock after buying an additional 2,307 shares during the period. Hexagon Capital Partners LLC’s holdings in Pfizer were worth $1,412,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Investor s Fiduciary Advisor Network LLC raised its stake in Pfizer by 16.5% in the first quarter. Investor s Fiduciary Advisor Network LLC now owns 29,207 shares of the biopharmaceutical company’s stock valued at $740,000 after buying an additional 4,141 shares in the last quarter. Tradewinds LLC. raised its stake in Pfizer by 21.8% in the first quarter. Tradewinds LLC. now owns 11,423 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 2,046 shares in the last quarter. Meridian Investment Counsel Inc. raised its stake in Pfizer by 7.2% in the first quarter. Meridian Investment Counsel Inc. now owns 69,874 shares of the biopharmaceutical company’s stock valued at $1,771,000 after buying an additional 4,717 shares in the last quarter. McGlone Suttner Wealth Management Inc. raised its stake in Pfizer by 63.6% in the first quarter. McGlone Suttner Wealth Management Inc. now owns 20,023 shares of the biopharmaceutical company’s stock valued at $507,000 after buying an additional 7,784 shares in the last quarter. Finally, Sierra Ocean LLC raised its stake in Pfizer by 117.3% in the first quarter. Sierra Ocean LLC now owns 2,757 shares of the biopharmaceutical company’s stock valued at $70,000 after buying an additional 1,488 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on PFE. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Redburn Atlantic dropped their price objective on Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. TD Cowen dropped their price objective on Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a report on Tuesday, April 22nd. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $28.55.

Pfizer Stock Performance

NYSE PFE opened at $25.45 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The business’s 50-day moving average price is $23.72 and its 200 day moving average price is $24.82. The firm has a market cap of $144.66 billion, a P/E ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the company earned $0.82 EPS. The firm’s revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.